Abstract
The transformation of a normal cell to cancer requires the derail of multiple pathways. Normal signaling in a cell is regulated at multiple stages by the presence of feedback loops, calibration of levels of proteins by their regulated turnover, and posttranscriptional regulation, to name a few. The tumor suppressor protein FBXO31 is a component of the SCF E3 ubiquitin ligase and is required to arrest cells at G1 following genotoxic stresses. Due to its growth-suppression activity, it is underexpressed in many cancers. However, the molecular mechanism underlying the translational regulation of FBXO31 remains unclear. Here we show that the oncogenic microRNAs miR-93 and miR-106a repress FBXO31, resulting in the upregulation of Slug, which is involved in epithelial-mesenchymal transition and cell invasion. FBXO31 targets and ubiquitylates Slug for proteasomal degradation. However, this mechanism is repressed in breast tumors where miR-93 and miR-106a are overexpressed. Our study further unravels an interesting mechanism whereby Slug drives the expression of miR-93 and miR-106a, thus establishing a positive feedback loop to maintain an invasive phenotype. Together, these results establish the presence of interplay between microRNAs and the ubiquitination machinery, which together regulate cancer cell invasion.

Introduction
Breast cancer is one of the leading causes of death worldwide and is the second most common cancer in women. Over 1.3 million cases of invasive breast cancer are diagnosed worldwide, and more than 450,000 women die of breast cancer each year. Although significant progress has been made in understanding the pathology of breast cancer, for further improvement of therapy, it is important to identify new therapeutic targets. Understanding the molecular players involved in the regulation of breast cancer progression and metastasis is the key to developing improved treatment strategies. The ubiquitin-proteasome machinery is involved in many diseases including cancer [1]. Inhibitors and activators of E3 ubiquitin ligases are promising targets for therapy, as they dictate the proteins to be ubiquitylated and the manner of their ubiquitylation. Therefore, an in-depth understanding of this class of genes is important.

FBXO31 is a member of the F-box protein family that plays an important role in cell cycle progression, DNA damage response, tumorigenesis, and neuronal development [2–6]. It is located on chromosome 16q24.3 and is inactivated in many cancers due to loss of heterozygosity [2]. It is a part of the SCF E3 ubiquitin ligase complex through association with SKP1, Cullin1, and RBX1. It targets multiple cellular substrates such as cyclin D1, MDM2, p38, ...
Cell Lines, shRNAs, and Plasmids

and Cdt1 and promotes their polyubiquitylation-mediated proteasomal degradation [5–8]. Previous studies show that it is a senescence-inducing gene and plays a predominant role in preventing BRAF-induced transformation [2–4]. More recently, it has been shown that it functions as a dedicated DNA damage checkpoint protein by arresting cells at G1 phase of the cell cycle through proteasomal degradation of cyclin D1 and by preventing MDM2-mediated proteasomal degradation of p53 [5,6].

Cellular proteins are maintained at the basal level through transcriptional, posttranscriptional, or posttranslational regulation. Posttranscriptional regulation has emerged as one of the major players in malignancy. Small noncoding RNAs, microRNAs (miRNAs), have emerged as crucial gene regulators at the posttranscriptional level, and their expression levels are frequently altered in cancer and other diseases [9,10]. MiRNAs are transcribed as a primary miRNA by RNA polymerase II or III [11]. This primary miRNA is processed by Drosha and Pasha to generate a precursor miRNA, which is further processed by Dicer to form the mature miRNA in the cytoplasm [12]. The mature miRNA then associates with the RISC complex to function as a posttranscriptional or translational regulator. It is estimated that more than 60% of human proteins coding genes are regulated by miRNAs [13].

MiRNAs are involved in the regulation of various biological processes such as cell proliferation, differentiation, tumorigenesis, angiogenesis, and metastasis [14–22]. Previous studies reported that miRNA clusters such as miR-106a-363 and miR-106b-25 play an important role in breast cancer malignancy [23,24]. In addition, miR-106b-25 cluster is reported to function as an oncogene in hepatocellular carcinoma, and miR-93, a member of miR-106b-25 cluster, acts as an oncogene in human glioblastoma [20,25,26].

Given the predominant role of FBXO31 in growth arrest and DNA damage checkpoint activation, it becomes important to understand its comprehensive regulation. In this study, we identified miR-93 and miR-106a as negative regulators of FBXO31 during normal cellular growth, but they fail to do so under genotoxic stresses. Further, we showed that these miRNAs promote scratch wound healing and cellular invasion through stabilization of Slug, which in turn is proteasomally degraded by FBXO31. Most interestingly, we unraveled that Slug directly drives the expression of miR-93 and miR-106a by binding to their promoter. Our study thus expands the understanding of molecular mechanisms involved in onset and progression of cancer by highlighting the presence of a feedback loop involving miR-93, miR-106a, FBXO31, and Slug for the first time.

Material and Methods

Cell Lines, shRNAs, and Plasmids

The human breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-435, T47D, and NCI/ADR-Res were provided by Prof. Michael R. Green (University of Massachusetts Medical School, USA). MCF7 cells were grown in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) medium, and rest of the cell lines were grown in RPMI media containing 10% FBS at 37°C in an atmosphere of 5% CO2 under humid conditions. pCMV-myc-FBXO31 and F-box domain deletion mutation vector pCMV-myc-FBXO31AF were kindly provided by Prof. David F. Callen (University of Adelaide, Australia). pSG5-Flag-hSlug was kindly provided by Prof. Sophie Tartare-Deckert (Bâtiment Universitaire Archimède, France). His-Ub was bought from Addgene [27].

pCMV-MIR vector and pMIR-REPORT vectors were kindly provided by Dr. Samit Chattopadhyay (National Centre for Cell Science, India).

FBXO31 knockdown cell lines were generated by stable transduction of MCF7 cells with the following lentiviral shRNAs as described previously [5]. Lentiviral shRNA clones were kindly provided by Prof. Michael R. Green, University of Massachusetts Medical School, USA.

Stable Knockdown Cells Generation

HEK-293T cells were seeded 1 day prior to transfection. Lentiviral shRNA plasmid along with lentiviral packaging plasmids (pPAX2 and pMD2.G) was co-transfected using polyethyleneimine. Transfection mixture was incubated at room temperature for 30 minutes and then added dropwise to the cells. Virus soup was collected after 48 hours of transfection and filtered through 0.45-μm syringe filter. MCF7 cells were transduced with filtered virus soup in the presence of 8 μg/ml of polybrene. Infected cells were selected by treating with 1 μg/ml of puromycin.

Cloning of miRNA and 3’ UTR Reporter System

Human miR-20b, miR-93, miR-106a, and miR-106b were amplified using genomic DNA as template, and the amplified polymerase chain reaction (PCR) product was inserted into XhoI site of the pCMV-MIR vector by using Infusion cloning kit according to manufacturer’s protocol (Takara). The point mutants of miRs were generated by Quik Change site-directed mutagenesis kit. The 3’UTR sequence (1065 bp) of human FBXO31–bearing miRNAs binding sites was amplified and inserted into the SpeI and HindIII sites of the pMIR-REPORT luciferase vector (named as Luc-WT). Seed sequence of miR-93 and miR-106a in the 3’UTR of FBXO31 was mutated by Quik Change site-directed mutagenesis kit. The mutants were named as Luc-Mut1 and Luc-Mut2.

Primer sequences were as follows:

Luc-WT (forward): 5’-ACCACTAGTCACATCTCTTGCCCGCACAT-3’
Luc-WT (reverse): 5’-GACAAGCTTGGAGGCATCAGTCCA-3’
Luc-Mut1 (forward): 5’-GAATAGAAGCATGGCGAGTTGGAAATTCGGCC-3’
Luc-Mut1 (reverse): 5’-GGCGGGATTTCACACTCGCATGCTGTTCTATTC-3’
Luc-Mut2 (forward): 5’-CAGTCCAGACACCCCCCAAGCGAGTTATGTAGAGAAGCAGTTGCGACTGCTG-3’
Luc-Mut2 (reverse): 5’-CTCTTACATACTCGTGGGCGTGCGCTGGACTGCTG-3’

Mut miRNA-93 (forward): 5’-GGGGGGCTCAAAATTTATCTGTGTTGCGG-3’
Mut miRNA-93 (reverse): 5’-GACAGACAGAAATTATTTGGAGCCCGGAC-3’
Mut miRNA-106a (forward): 5’-GAGGGGCTCAAAATTTATCTGTTTGTCAAG-3’
Mut miRNA-106a (reverse): 5’-GCAGAGACAGAAATTATTTGGAGGGCGGAC-3’. Cell Transfection

Cells were seeded 1 day prior to transfection, and polyethyleneimine (PEI 25000 from Polysciences, USA) was used as transfection reagent. Transfection mixture was prepared the following day in
150 mM NaCl solution by mixing DNA and polyethylenimine [DNA (μg):polyethylenimine (μg)] in a ratio of 1:2.4. Transfection mixtures were incubated at room temperature for 15 minutes and then added to the media in dropwise manner.

**Dual Luciferase Assay**

MCF7 cells were seeded in a 24-well plate, and cells were transfected with indicated plasmids using polyethylenimine as described above. The cells were harvested and lysed after 48 hours of transfection. Luciferase activity was measured according to the manufacturer’s protocol (Dual-Luciferase Reporter Assay System; Promega, Madison, WI), and Renilla luciferase was used for normalization.

**Quantitative Real-Time Reverse Transcriptase PCR (qRT-PCR)**

TRizol reagent (Invitrogen) was used to extract total RNA according to the manufacturer’s protocol. The first-strand cDNA was synthesized with random primers or miRNA stem loop specific primers and Multiscribe™ reverse transcriptase (Applied Biosystems). Quantitative real-time PCR was performed in the Eppendorf Master Cycler RealPlex using SYBR Green Kit from Takara. Fold change was calculated as described previously [28].

Primer sequences were as follows:

FBXO31 (forward): 5'-GGATGTACCTGCCACCTCAT-3'.
FBXO31 (reverse): 5'-CCACTGTAGCCGACTTCTC-3'.
Slug (forward): 5'-ACAGAGCATTGTGCAAGAGG-3'.

**Figure 1.** MiR-93 and 106a negatively regulate the expression of FBXO31 at the protein level by binding to its 3’UTR. (A) Relative luciferase activity in the presence of miRNAs. Luciferase assay was performed with pCMV-MIR vector containing the 3’UTR of FBXO31. Luciferase reported vector was co-transfected with either empty vector or miRNAs for 48 hours in MCF7 cells. The data were normalized to empty vector, and results are presented as mean ± SD, *P < .001. (B) MiR-93 and miR-106a repressed the translational level of FBXO31. MCF7 cells were transfected with indicated miRNAs and were harvested at 48 hours posttransfection. Whole cell protein extracts were immunoblotted with indicated antibodies. Tubulin was used as loading control. (C) MiR-93 targets first seed sequence, whereas miR-106a needs both the seed sequences. Luciferase activity was measured after 48 hours of co-transfection with indicated plasmids. The data for wild-type 3’UTR of FBXO31 were normalized to empty vector, and the rest of the data were normalized to wild-type 3’UTR of FBXO31. The data are presented as mean ± SD, *P < .001. (D and E) MiR-93 and miR-106a regulate FBXO31 in a dose-dependent manner. Indicated plasmids were transfected (0-, 1-, 2-, and 3-fold) for 48 hours, and then whole cell protein extracts were immunoblotted with indicated antibodies. (F and G) Mutant-miRs interfere in the function of miR-93 and miR-106a. Cells were transfected with miR-93/miR-106a with or without their respective mutant miRNA for 48 hours. Whole cell protein extracts were immunoblotted with indicated antibodies. Tubulin is used as loading control. (H and I) MiR-93 and 106a alter the FBXO31 protein level. Pulse chase cycloheximide assay was performed by overexpression of microRNAs, and different time points were collected after treatment with cycloheximide. (I) Quantitative representation of pulse chase cycloheximide assay.
Figure 2. MicroRNAs-93 and 106a fail to regulate FBXO31 in response to genotoxic stresses. (A) Luciferase activity of FBXO31 3′UTR reporter increased upon treatment of IR. MCF7 cells were transfected with FBXO31 3′UTR luciferase construct, and luciferase activity was measured with and without irradiation. Cells were collected at 4 hours postirradiation. (B–E) Ectopically expressed microRNAs failed to prevent FBXO31 stabilization under genotoxic stresses. MCF7 cells were transfected with indicated miRNAs for 48 hours. The transfected cells were exposed to either IR (B and C) or etoposide treatment (D and E). Whole cell protein extracts were immunoblotted with indicated antibodies. (F and G) MicroRNA levels decreased under stress conditions. MCF7 cells were treated with either IR or Etoposide, total RNA was isolated, and cDNA was prepared followed by real-time RT-PCR.

Slug (reverse): 5′-TGCTACACAGCACGCAGAT-3′.
E-Cadherin (forward): 5′-AAGGTGACAGAGCCTCTGGAT-3′.
GAPDH (forward): 5′-TGCCGGTGACTAACCCTGCG-3′.
mir-93: stem loop: 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCTACCT-3′.
mir-93 (forward): 5′-TTAACAAAGTGCTGTTCGTGC-3′.
mir-106b (forward): 5′-TTAACAAAGTGCTGACAGTGC-3′.
mir-20b (forward): 5′-TTAACAAAGTGCTCATAGTGC-3′.
mir-106a (forward): 5′-TACTAAAAGTGCTTACAGTGC-3′.
mir-106b (forward): 5′-TACGCGGCCGCTCGAGGCCTTTTCCCCACTTCTTAA-3′.
mir-93 (reverse): 5′-TGAGTTTCTGCTCGATCCCGGAATTCAGCTGTCC-3′.
mir-106a (reverse): 5′-TGAGTTTCTGCTCGACACATT-3′.
mir-106b (reverse): 5′-TGAGTTTCTGCTCGACTGAATATTAACTA-3′.
mir-20b (reverse): 5′-TGAGTTTCTGCTCGACTGAATATTCTCT-3′.
18S rRNA (forward): 5′-GTAACCCGTTGAACCCCATT-3′.
18S rRNA (reverse): 5′-CCATCCAATCGGTAGTAGCG-3′.
Immunoblotting Analysis

Cells were harvested, washed with ice-cold PBS, and then lysed with lysis buffer (50 mM Tris pH 7.4, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.5 mM Na orthovanadate, and 0.5% Triton X-100) to prepare protein extracts. Protein concentrations were measured by the Bradford method using bovine serum albumin as standard [29]. The proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a PVDF membrane and were probed with specific primary antibody kept overnight at 4°C with gentle rocking. Antibodies against FBXO31, Flag, β-actin, and α-tubulin were procured from Sigma. TP53 antibody was purchased from Santa Cruz, Slug from Abcam, E-cadherin from BD Biosciences, and c-myc from Roche. Snail, Twist, and K48-ubiquitin antibodies were purchased from Cell Signaling Technology. β-Actin and α-tubulin were used as loading control.

Cycloheximide Pulse Chase Assay

MCF7 cells were treated with cycloheximide (40 μg/ml) for indicated time points. Cells were then harvested, washed with ice-cold PBS, and lysed with lysis buffer as described above. Immunoblotting was performed with mentioned antibodies. Band intensity was measured using ImageJ software and was normalized with loading control. Protein at 0-hour time point was taken as 100%, and the percentage of remaining protein was calculated with respect to 0 hour.

Co-Immunoprecipitation Assay

MCF7 cells were co-transfected with Flag-Slug and myc-FBXO31 for 36 hours and then treated with MG132 (5 μM; Calbiochem) for an additional 8 hours. Six hundred micrograms of protein extract was incubated with indicated antibodies for 10 to 14 hours at 4°C with gentle rocking. Then, protein G agarose beads were added to protein-antibody mixture and incubated for an additional 1.5 hours.
Unbound proteins and antibody were separated by washing the beads three times, and immunoprecipitates were eluted from beads by boiling with sample buffer for 5 minutes. Eluted immunoprecipitates were resolved by SDS-PAGE followed by immunoblotting with indicated antibodies.

**Ubiquitination Assay**

MCF7 cells were co-transfected with mentioned plasmids. After 36 hours of transfection, cells were treated with 5 μM MG132 for an additional 8 hours. Protein extracts were incubated overnight with Ni-NTA beads at 4°C with gentle rocking. The beads were washed...
three times using lysis buffer with an intermittent incubation of 5 minutes each. The bound proteins were eluted by boiling with sample buffer as described above. The eluted proteins were separated through SDS-PAGE and immunoblotted with indicated antibodies.

**Scratch Wound Healing Assay**

Scratch wound healing assay was performed as described previously [30]. Briefly, transfected MCF7 cells were scratched with 200-µl tip to generate the open space. Cells were grown in DMEM supplemented with 5% FBS containing 5 ng/ml of actinomycin D to prevent the cell proliferation. The open space was tracked using live cell imaging microscope (Nikon Time Lapse microscope model TE 2000E). The percentage of open area was calculated using Tscratch software.

**Cell Invasion Assay**

Invasion experiment was performed as described previously [31]. Briefly, transfected cells (2 × 10⁴/well) were suspended in serum-free DMEM in the upper chamber, and the lower chamber was loaded with complete DMEM. After 12 hours, the invaded cells were stained with 0.5% crystal violet. Images were taken with Nikon photograph camera.

**Colony Formation Assay**

Colony formation assay was performed as described previously [5]. Briefly, transfected MCF7 cells (5 × 10³) were seeded in 35-mm plate and were grown in complete DMEM containing 0.8 mg/ml of G418 for 3 weeks. Then, the cells were fixed with 3.7% formaldehyde solution followed by staining with 0.5% crystal violet. Stained cells were then washed with PBS three times with gentle rocking at room temperature to remove the residual crystal violet solution.

**Senescence Associated β-Gal Staining**

MCF7 cells were co-transfected with indicated plasmids. Cells were then treated with γ-rays (10 Gy) and were grown at 37°C for 7 days. Senescence associated β-gal staining was performed as previously described [32]. Briefly, cells were fixed with 3.7% formaldehyde for 15 minutes and were incubated at 37°C with staining solution [150 mM NaCl, 2 mM MgCl₂, 5 mM K₃ Fe(CN)₆, 5 mM K₂Fe(CN)₆, 40 mM citric acid, and 12 mM sodium phosphate [pH 6.0] containing 1 mg/ml of 5-bromo-4-chloro-3-indolyl-D-galactoside]. Digital pictures were taken on an Olympus TH4-200 by 20× objective lens.

**RNA Immunoprecipitation (RIP)**

RIP was performed to confirm the binding of miR-93 and miR-106a to the 3’UTR of FBXO31. RIP was performed as described previously [33]. Briefly, after 36 hours of transfection, cells were γ-irradiated (10 Gy) and kept for an additional 12 hours. The cells were then UV cross-linked (50 mJ/cm²) followed by fixation with 3.7% formaldehyde and quenching with 2 M glycine. The lysates were then incubated for 2 hours at 4°C with antibody-coated protein G agarose beads. Then, RNA was extracted from bound complex using TRIzol. cDNA was prepared, and PCR was performed to detect miRNA and 3’UTR of FBXO31 using specific primers.

**Immunohistochemistry (IHC)**

The tissue samples were obtained from SDM College of Medical Sciences, as per established core procedures and Institutional Ethical
Board approval. Tissue samples were stained with hematoxylin-eosin to determine the histological type and grade of tumors. Twenty tissue samples from breast cancer patients, including cancerous tissue and adjacent nonmalignant epithelium, were analyzed for FBXO31 and Slug using immunohistochemical staining as described previously [34]. In brief, after deparaffinization and endogenous peroxidase blockage, the sections were heated in 0.01 M citrate buffer solution (pH 6.0) in water bath at 98°C for 20 minutes; then incubated with the rabbit and goat polyclonal antibody to FBXO31 and Slug (Santa Cruz Biotechnology), respectively, at 1:100 dilution overnight at 4°C; and visualized using 3,3′-diaminobenzidine detection kit (Vector labs). For the negative control, anti-rabbit and anti-goat IgG whole molecule (Sigma-Aldrich) was used at 1:1000 dilution. IHC-stained samples were evaluated by two pathologists, and all samples were blinded. Staining intensity of these proteins in neoplastic cells was graded on a scale of 0 (no staining) to 3+ (strong staining). The protein expression was scored based on the percentage of positive cells: score 0 = 0% of stained positive cells; score 1 = weakly stained tissue or 1%-25% of positive cells; score 2 = moderate stained tissue or 26%-50% of positive stained cells; and score 3 = strongly stained tissue or more than 50% of stained cells.

Chromatin Immunoprecipitation (ChIP)

ChIP was performed as described previously [35]. Briefly, MCF7 cells treated with and without etoposide (5 μM for 12 hours) were cross-linked with 3.7% formaldehyde for 15 minutes at room temperature with gentle rocking. Cross-linking reaction was quenched by addition of 125 mM glycine for 10 minutes. The cell lysates were sonicated to generate fragmented DNA-protein complex and were then incubated with anti-Slug antibody overnight at 4°C. Preblocked protein A agarose beads were incubated with lysate-antibody complex for 2 hours followed by reverse cross-linking by proteinase K. DNA was eluted by phenol-chloroform method. PCR was performed using microRNA specific primers.
The following primers were used for PCR.

miR-93 region 1 (forward): 5′-GGGGACCATGTTAAATGGGGA-3′.
miR-93 region 1 (reverse): 5′-GCCCTCCAGCAATTTGGGCAC-3′.
miR-93 region 2 (forward): 5′-ACGTGGAGATGAGGCGAGAGG-3′.
miR-93 region 2 (reverse): 5′-TTCCCTCCACGGACGCTGTGC-3′.
miR-93 region 3 (forward): 5′-GCTACCGCACTGTGGGTACTT-3′.
miR-93 region 3 (reverse): 5′-GGAGCTCAGCCAAGAAGACAA-3′.

Statistical Analysis

Each experiment was repeated at least three times. Values shown are standard deviation (SD) except otherwise mentioned, and data were represented as mean ± SD. Statistical analysis was performed by using Sigma Stat 4.0 (Systat Software Inc., San Jose, CA). Student’s t test was performed to analyze the statistical significance. The values *P < .01 and **P < .001 denote significant differences between the groups (n ≥ 3 at the least).

Results

MicroRNAs 93 and 106a Suppress the Translational Level of FBXO31 via Binding to Its 3′UTR

To explore the possible involvement of miRNA-mediated regulation of FBXO31 expression, an in silico analysis was performed by using online computational algorithm as mentioned in Materials and Methods. In silico analysis revealed that the 3′UTR of FBXO31 has putative binding sites for six potential microRNAs (Supplementary Table 1). These microRNAs have two similar putative binding sites on the 3′UTR of FBXO31 which are conserved among mammals: a 7-mer-m8 seed sequence AGCACTTTA (75-81 bp from the start of 3′UTR) and a 8-mer seed sequence ATGCACTTTG (145-152 bp from the start of 3′UTR) (Supplementary Figure 1A).

We evaluated the effect of in silico predicted miRNAs on the expression of FBXO31 using a luciferase reporter assay. The activity of luciferase reporter containing the FBXO31 3′UTR was suppressed to different extents in the presence of miRNAs -20b, -93, -106a, and -106b (Figure 1A). Next, immunoblotting data revealed that these miRNAs also suppressed the level of FBXO31 (Figure 1B). Among these miRNAs, miR-93 and miR-106a showed the potent effects on FBXO31 expression without affecting mRNA level (Figure 1B and Supplementary Figure 1B). However, these miRNAs do not regulate FBXO31 synergistically (Supplementary Figure 1C). Based on above results, we selected these two miRNAs to understand the molecular mechanism of FBXO31 regulation.

Next, to confirm the specificity of miR-93– and miR-106a–mediated regulation of FBXO31, we generated mutants by altering the seed sequence of miR-93 and miR-106a in the 3′UTR of FBXO31 luciferase reporter (Supplementary Figure 1D). Results revealed that the luciferase activity was significantly increased upon mutation of either of the seed sequences (Fig. 1C). Analysis of the results demonstrated that miR-106a requires both seed matches, whereas miR-93 preferentially targets the first seed sequence for regulating FBXO31. Further, RNA immunoprecipitation was performed to confirm that these miRNAs bind to the 3′UTR of FBXO31 (Supplementary Figure 1, E–H).

Next, a dose-dependent increase of either miR-93 or miR-106a resulted in the decrease in FBXO31 levels (Figure 1, D and E). This effect was abolished by co-expression of point mutant of these microRNAs (Figure 1, F and G). In addition, cycloheximide pulse chase assay revealed that miR-93 or miR-106a significantly reduced the stability of FBXO31 (Figure 1, H and I).

MicroRNAs-93 and 106a Fail to Regulate FBXO31 in Response to Genotoxic Stresses

A previous study showed that FBXO31 stabilizes under various genotoxic stresses, suggesting that regulation of FBXO31 may be different under these conditions [5]. Hence, the involvement of miR-93 and miR-106a in the regulation of FBXO31 under genotoxic stress was examined. In agreement with the previous report, luciferase activity of FBXO31 3′UTR and the endogenous FBXO31 levels were significantly increased upon ionizing radiation (IR) (Figure 2A and Figure 7. Proposed model describes feedback loop in FBXO31, Slug, and miRNAs in normal (left) and genotoxic stress (right) conditions.
Interestingly, ectopic expression of miR-93 and miR-106a did not affect the stabilization of FBXO31 in response to IR (Figure 2, B and C) and etoposide treatment (Figure 2, D and E). This effect was further evident from our cell cycle data wherein overexpression of these miRNAs could not prevent the FBXO31-mediated G1 arrest (Supplementary Figure 2B). These results taken together suggest that miRNAs could not suppress FBXO31 expression either due to their inability to bind the FBXO31 3′UTR or due to an alteration of their expression levels. Interestingly, the levels of miR-93 and miR-106a were found to be significantly decreased upon IR (Figure 2F) and etoposide treatment (Figure 2G). Further, RNA immunoprecipitation data demonstrated that these miRNAs are incapable of binding to 3′UTR of FBXO31 under genotoxic stress (Supplementary Figure 1, D–G). Collectively, these results suggest that although miR-93 and miR-106a repress FBXO31 under normal conditions, they were unable to do so under genotoxic stresses due to their reduced expression as well as their reduced binding at the 3′UTR of FBXO31.

**FBXO31 Suppresses Cell Invasion and Migration by Downregulating the EMT Regulator Slug**

Owing to its growth suppressive effect, expression of FBXO31 is maintained at low level under normal growth conditions. Examination of the levels of miRNAs in different breast cancer cell lines revealed an increase in levels of both miR-93 and miR-106a in most cell lines (Supplementary Figure 3A). We further found that ectopic expression of miR-93 and miR-106a led to a significant increase in the number of colonies formed in the long-term survival assay, which may be partly due to inactivation of FBXO31 (Figure 3A). This is in agreement with the previous reports showing the oncogenic function of miR-93 and miR-106a [20,25,26]. Further, most of the oncogenes promote the cellular transformation through activation of EMT. We therefore tested the effect of miR-93 and miR-106a on scratch wound healing and invasion. Results demonstrated that ectopic expression of miR-93 and miR-106a promotes both scratch wound healing and invasion, suggesting that these miRNAs may regulate EMT promoters (Figure 3, B and C, and Supplementary Figure 3, B and C). Slug is among the well-established EMT regulators (Figure 3B). FBXO31 suppresses cell invasion and migration by FBXO31 (Supplementary Figure 3F). Collectively, these results suggest that miR-93 and miR-106a promote cell survival and accelerate wound healing as well as invasion by stabilization of Slug through suppression of FBXO31.

**FBXO31 Promotes the Ubiquitination and Proteasomal Degradation of Slug**

The above results suggest that FBXO31 antagonizes the function of Slug presumably by negatively regulating its levels. Because FBXO31 is part of an E3 ubiquitin ligase, we sought to ask whether it is directly involved in the proteasomal degradation of Slug. FBXO31 failed to cause degradation of Slug in the presence of proteasome inhibitor MG132, suggesting that FBXO31 regulates Slug in a proteasome-dependent manner (Figure 4A). Further, we found that ectopic expression of a mutant form of FBXO31 lacking the F-box motif (ΔF-FBXO31) failed to downregulate Slug, indicating that FBXO31 regulates Slug through the SCF E3 ubiquitin ligase complex (Figure 4B). Furthermore, co-immunoprecipitation experiments indicated that FBXO31 physically interacts withSlug (Figure 4C and Supplementary Figure 4A) and facilitates its polyubiquitination (Figure 4D and Supplementary Figure 4B). Recent reports suggested that GSK3β-mediated phosphorylation of Slug facilitates its turnover [36]. However, inhibition of GSK3β did not stabilize Slug levels in the presence of FBXO31, indicating that FBXO31 does not need GSK3β-mediated phosphorylated form of Slug for its proteasomal degradation (Supplementary Figure 4C).

Next, we sought to determine whether FBXO31 regulates Slug at the physiological level and found that knockdown of FBXO31 resulted in a significant stabilization of Slug (Figure 4E). In addition, cycloheximide pulse chase study also revealed an enhanced stability of Slug in FBXO31 knockdown cells (Figure 4, F and G). Knockdown of FBXO31 also resulted in decreased levels of polyubiquitylated Slug (Figure 4H). Collectively, our results demonstrated that FBXO31 maintains the cellular level of Slug.

Our initial observations have indicated that miR-93 and miR-106a are suppressed and FBXO31 is stabilized upon genotoxic stresses. Hence, we further sought to understand the expression levels of Slug under genotoxic stresses. Interestingly, immunoblotting data indicated that Slug is decreased under genotoxic stress conditions (Figure 4I). To check whether FBXO31 has any role in Slug regulation under genotoxic stress, FBXO31 knockdown and control cells were exposed to genotoxic agents like etoposide and IR. Results showed that FBXO31 destabilizes Slug under genotoxic stress (Figure 4J and Supplementary Figure 4D).

**Reciprocal Expression Pattern of FBXO31 and Slug in Breast Cancer Progression**

Our *in vitro* data suggest that FBXO31 negatively regulates Slug, prompting us to check their levels in different breast cancer cell lines as well as patient samples. Results showed the existence of an inverse correlation between Slug and FBXO31 levels in most of the breast cancer cell lines (Figure 5A). Next, to investigate the expression levels of FBXO31 and Slug in breast cancer patient samples, immunohistochemical staining of patient tissue with matched normal breast tissue was performed. Our data indicate that FBXO31 is expressed in all noncancerous tissues (Figure 5, B and C). However, as cancer progressed from grade I to grade III, FBXO31 staining intensity decreased, and high-grade breast cancer tissue samples exhibited negative staining. On the other hand, Slug expression was low/null in...
normal tissue and was significantly increased in grade I to III in infiltrating ductal carcinoma. The expression pattern of Slug significantly correlated with tumor size, stage of the cancer, and tumor grade as shown in the figure (Figure 5, B and C).

**FBXO31 Regulates a Feedback Loop Wherein Slug Drives miR-93 and miR106a Expression**

Previous reports have demonstrated that Slug regulates microRNAs at the transcriptional level by binding to the E-box motif in the promoter region [37]. Our results also hint to the existence of a cross talk between miRNAs, FBXO31, and Slug. Therefore, we went on to check if Slug regulates miR-93 and miR-106a as well and found that it regulates these miRNAs at the transcriptional level (Figure 6A). We further checked the effect of FBXO31 on the levels of miRNAs because it degrades Slug. Interestingly, levels of both the miRNAs were decreased upon ectopic expression of FBXO31, and their levels were elevated upon depletion of FBXO31 (Figure 6B, B and C). These results taken together indicate that FBXO31 may regulate miRNA levels through Slug. To validate the involvement of Slug in driving miRNA expression, we performed ChIP to determine whether Slug binds to E-box sequences present at the promoter of miR-93 (Figure 6D, upper panel). ChIP results revealed that Slug binds to the third E-box region (R3) of miR-93 under normal condition, which is significantly inhibited upon etoposide treatment (Figure 6D, lower panel).

Because FBXO31 is a known inducer of senescence, we investigated the effect of miR-93 and miR-106a on FBXO31-mediated senescence [2,4,5]. The senescence-associated β-galactosidase staining showed that overexpression of miR-93 and miR-106a inhibits senescence that is induced by FBXO31 (Figure 6E). Collectively, our study demonstrates that miR-93 and miR-106a act as oncogene by interfering with the tumor suppressive function of FBXO31 and provides the evidence for existence of a feedback mechanism between FBXO31, Slug, miR-93, and miR-106a (Figure 7).

**Discussion**

FBXO31 is a member of the F-box family, which functions as a substrate-recognition unit in SCF (Skp1, Cullin1, Rbx1, and F-box) E3 ubiquitin ligase complex and mostly targets the phosphorylated substrates [5]. Initial studies reported that FBXO31 functions as a tumor suppressor in many cancers such as breast cancer [2], melanoma [5], hepatocellular carcinoma [38], and gastric cancer [39]. It induces senescence by arresting cells at the G1 phase of the cell cycle through proteasomal degradation of either cyclin D1 or MDM2 or both [4–6]. Having growth suppressive effect and involvement in DNA damage response pathway, posttranslational level of FBXO31 is maintained at a low level under normal growth condition. These findings encouraged us to investigate the regulation of FBXO31.

Previous unpublished data demonstrate that FBXO31 is not regulated at the transcriptional level throughout the cell cycle (data not shown). Hence, we examined the possibility of regulation of FBXO31 at the posttranscriptional level by miRNAs. In support of this, our *in silico* analysis predicted four miRNAs (miR-17, miR-20, miR-93, and miR-106a) to be involved in the regulation of FBXO31 at the translational level. Recently, miR-17 and miR-20 have been reported to regulate FBXO31 in gastric cancer [39]. Our study revealed that miR-93 and miR-106a significantly suppressed the FBXO31 expression. This led us to investigate the regulation of FBXO31 by these miRNAs in detail.
References

[1] Wang Z, Liu P, Inuzuka H, and Wei W (2014). Roles of F-box proteins in cancer. Nat Rev Cancer 14, 233–247.
[2] Kumar R, Neilsen PM, Crawford J, McBride R, Lee J, Powell JA, Saif Z, Martin JM, Lambaerts M, Callen DF, et al (2005). FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Res 65, 11304–11313.
[3] Vadhvanii M, Schwedhelm-Domeyer N, Mukherjee C, and Segmüller J (2013). The centrosomal E3 ubiquitin ligase FBXO31-SCF regulates neuronal morphogenesis and migration. PLoS One, e57530.
[4] Wajapeeey N, Serra RW, Zhu X, Mahalingam M, and Green MR (2008). Oncogenic BRF induces senescence and apoptosis through pathways mediated by the secreted ligand IGFBP7. Cell 132, 363–374.
[5] Santra MK, Wajapeeey N, and Green MR (2009). F-box protein FBXO31 mediates cyclin D1 degradation to induce G1 arrest after DNA damage. Nature 459, 722–725.
[6] Malonia SK, Dutta P, Santra MK, and Green MR (2015). F-box protein FBXO31 directly degrades of MDM2 to facilitate p53-mediated growth arrest following genotoxic stress. Proc Natl Acad Sci U S A 112, 8632–8637.
[7] Liu J, Han L, Li Y, Jiang Y, Huen MS, and Cheung AL (2014). F-box only protein 31 (FBXO31) negatively regulates p38 mitogen-activated protein kinase (MAPK) signaling by mediating lysine 48-linked ubiquitination and degradation of mitogen-activated protein kinase 6 (MAPK6). J Biol Chem 289, 21508–21518.
[8] Johannson P, Jeffery J, Al-Ejleh F, Schulz RB, Callen DF, Kumar R, and KK Khanna (2014). SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication. J Biol Chem 289, 18514–18525.
[9] Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
[10] Sato-Kuwabara Y, Molé SA, Soares FA, and Calin GA (2015). The fusion of two worlds: non-coding RNAs and extracellular vesicles—diagnostic and therapeutic implications. Int J Onco 46, 17–27.
[11] Lee Y, Jeon K, Lee JT, Kim S, and Kim VN (2002). MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 21, 4663–4670.
[12] Lee Y, Ahn C, Han J, Choi K, Kim J, Yim J, Lee J, Provost P, Rádzmak O, Kim VN, et al (2003). The nuclear RNase III Drosha initiates microRNA processing. Nature 496, 356–360.
[13] Friedman RC, Farh KK, Burge CB, and Bartel DP (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19, 92–105.
[14] Virchció G, Lena AM, Latina A, Formosa A, Gregeresen LH, Lund AH, Bernardini S, Mauriello A, Miano R, Melino G, et al (2011). MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. JBiolChem 286, 221–230.
[15] Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, Gobeil S, and Green MR (2009). Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNM3TB expression. Mol Cell 36, 219–230.
[16] Kao SH, Wang WL, Chen CY, Chang YL, Wu YW, Yang WT, Wang SP, Nowicki AK, Chen YJ, and Yang PC (2014). GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHK-mediated degradation of Slug. Oncogene 33, 3172–3182.
[17] Aomatsu K, Arao T, Abe K, Kodama A, Sugioka K, Matsumoto K, Kudo K, Kimura H, Fujita Y, Nishikou K, et al (2012). Slug is up-regulated during PDCD4 in gastric carcinoma. Oncotarget 3, 174–185.
[18] Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Anderson MR, et al (2005). Real-time quantification of microRNAs by stem–loop RT–PCR. Nucleic Acids Res 33, e179.
[19] Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72, 248–254.
[20] Cory Giles (2013). Scratch-wound assay. Methods Mol Biol 769, 25–30.
[21] Jan HJ, Lee CC, Shih YL, Huang DY, MA HI, Lai JH, Wei HW, and Lee HM (2010). Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 12, 58–70.
[22] Itahana K, Itohana Y, and Dimri GP (2013). Colorimetric detection of senescence-associated β galactosidase. Methods Mol Biol 965, 143–156.
[23] Gilber C and Svejstrup JQ (2006). RNA immunoprecipitation for determining RNA-protein associations in vivo. Curr Protoc Mol Biol (Chapter 27: Unit 7.24).
[24] Shetty P, Bargale A, Patil BR, Mohan R, Dinesh US, Vishwanatha JK, Pramod BG, Vidya SP, and Ansavardani TS (2016). Cell surface interaction of annexin A2 and galectin-3 modules epidermal growth factor receptor signaling in Her-2 negative breast cancer cells. Mol Cell Biochem 411, 221–235.
[25] Palakurthy RK, Wajapeyee N, Santra MK, Gazin C, Lin L, Gobeil S, and Green MR (2009). Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNM3TB expression. Mol Cell 36, 219–230.
[26] Kao SH, Wang WL, Chen CY, Chang YL, Wu YW, Yang WT, Wang SP, Nowicki AK, Chen YJ, and Yang PC (2014). GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHK-mediated degradation of Slug. Oncogene 33, 3172–3182.
[27] Aomatsu K, Arao T, Abe K, Kodama A, Sugioka K, Matsumoto K, Kudo K, Kimura H, Fujita Y, Nishikou K, et al (2012). Slug is up-regulated during PDCD4 in gastric carcinoma. Oncotarget 3, 174–185.
[28] Huang HL, Zheng WL, Zhao R, Zhang B, and Ma WL (2010). FBXO31 is down-regulated and may function as a tumor suppressor in hepatocellular carcinoma. Oncol Rep 33, 715–720.
[29] Zhang X, Kong Y, Xu X, Xing H, Zhang Y, Liu Z, et al (2014). F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. Oncotarget 5, 6178–6190.
[30] Liang H, Wang F, Choi D, Zhang W, Liao Z, Fu Z, Yan X, Zhu H, Gao W, Chen X, et al (2016). miR-93 functions as an oncomiR for the downregulation of PDCD4 in gastric carcinoma. Sci Rep 6, 23772.
[31] Xiao I, Zhou L, Cao P, Gong H, and Zhang Y (2015). MicroRNA-93 regulates cyclin G2 expression and plays an oncogenic role in laryngeal squamous cell carcinoma. Int J Onco 46, 161–174.
[32] Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD, Pertsemlidis A, et al (2014). MiR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene 34, 4307–4315.
[33] Smirh AL, Ivanaga R, Drasen DJ, Micalizzi DS, Vartuli RL, Tan AC, and Ford HL (2012). The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Smad7 in human breast cancer. Oncogene 50, 5162–5171.
[34] Kim K, Chudalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, Park YK, Lee JS, and Safe S (2012). Identification of oncogenic microRNA-17-92/ZBTB4 specificity protein a5 in breast cancer. Oncogene 31, 1034–1044.
[35] Qu MH, Han C, Srivastava AK, Cui T, Zou N, Gao QZ, and Wang QE (2016). MiR-93 promotes TGF-β-induced epithelial-to-mesenchymal transition through downregulation of NEDD4L in lung cancer cells. Tumour Biol 37, 5645–5651.
[46] Jiang Lili, Wang Chanjuan, Lei Fangrong, Zhang Longjuan, Zhang Xin, Aibin Liu, Geyan Wu, Jinrong Zhu, and Song Libing (2015). MiR-93 promotes cell proliferation in gliomas through activation of PI3K/Akt signaling pathway. Oncotarget 6, 8286–8299.

[47] Fabbri E, Montagner G, Bianchi N, Finotti A, Borgatti M, Lampronti I, Cabrini G, and Gambari R (2016). MicroRNA miR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells. Oncol Rep 35, 2866–2872.

[48] Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, and Xu N (2013). MiR-106a is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Mol Carcinog 52, 634–646.

[49] Xie X, Liu HT, Mei J, Ding FB, Xiao HB, Hu FQ, and Wang MS (2015). MiR-106a promotes growth and metastasis of non–small cell lung cancer by targeting PTEN. Int J Clin Exp Pathol 8, 3827–3834.

[50] Liu Z, Gensbach E, Zhang X, Xu X, Dong R, Lee P, Liu J, Kong B, Shao C, and Wei JJ (2013). MiR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma. Mol Cancer Res 11, 1314–1325.

[51] Zhu M, Zhang N, He S, Lui Y, Lu G, and Zhao L (2014). MicroRNA-106a targets TIMP2 to regulate invasion and metastasis of gastric cancer. FEBS Lett 588, 600–607.